Skip to content
Open access

Efficacy and safety of rituximab in a multicentre Brazilian cohort of patients with generalized myasthenia gravis

Oct 2026 · ANPAbstract_CBN26 · 0 citations

Abstract

Background: Myasthenia gravis (MG) is an autoimmune neuromuscular disorder mediated by antibodies targeting components of the postsynaptic membrane at the neuromuscular junction. Up to 15% of patients develop refractory disease despite standard immunotherapies. Current guidelines recommend rituximab as a first-line option in MuSK-positive MG; however, its role in AChR-positive disease remains less well defined. Emerging evidence suggests that earlier use of rituximab may improve outcomes, and real-world data support its efficacy in refractory cases. Objective: To evaluate the efficacy of RTX in a multicentre Brazilian cohort of patients with generalized MG. Methods: Patients followed at six neuromuscular referral centres in Brazil were included. Clinical, epidemiological, and serological data were retrospectively collected using a standardized proforma. Disease severity was assessed using MGFA classification and MG-ADL scores at baseline and at 3 months. The number of exacerbations or myasthenic crises in the 24 months prior to RTX initiation was recorded. Post-intervention MGFA status, as well as changes in symptomatic and immunosuppressive therapies, were also evaluated. Results: Seventy-nine patients with generalized MG were included, of whom 62 (78.5%) were female. The mean age at onset was 38.5 ± 17.0 years. Disease onset occurred before 50 years of age in 55 patients (69.6%), including 11 with juvenile-onset and 44 with early-onset MG. Anti–acetylcholine receptor (AChR) antibodies were detected in 53 patients (67.1%), while 19 (24.1%) were positive for MuSK antibodies. Two patients were double seropositive, and four (5.1%) were seronegative. After RTX treatment, significant clinical improvement was observed. The mean number of exacerbations/crises decreased from 1.06 ± 1.43 to 0.16 ± 0.56 (p < 0.001). The proportion of patients with moderate-to-severe disease (MGFA ≥2B) decreased from 79.7% to 30.4% (p < 0.001). MG-ADL scores significantly improved, with median values decreasing from 8 (IQR 3–13) before treatment to 2 (IQR 1–4) after treatment (p < 0.0001), corresponding to a mean reduction of 5.38 points. After treatment, 43% of patients achieved MG-ADL scores of 0–1 and 78% had scores ≤5. RTX also demonstrated a significant steroid-sparing effect, with mean daily prednisone dose decreasing by 67% (p < 0.001). According to MGFA post-intervention status, 63.9% of patients achieved minimal manifestation status and 6.6% achieved complete stable remission. No severe adverse effects were reported among these patients. Conclusion: In this Brazilian cohort, rituximab was effective and well tolerated in refractory MG, leading to significant reductions in disease severity, crises, and treatment burden. RTX seems to be an effective therapeutic option for gMG.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.